Abstract Cannabinoids affect immune responses in ways that may be beneficial for autoimmune diseases. We sought to determine whether chronic Cannabis use differentially modulates a select number of immune parameters in healthy controls and individuals with multiple sclerosis (MS cases). Subjects were enrolled and consented to a single blood draw, matched for age and BMI. We measured monocyte migration isolated from each subject, as well as plasma levels of endocannabinoids and cytokines. Cases met definition of MS by international diagnostic criteria. Monocyte cell migration measured in control subjects and individuals with MS was similarly inhibited by a set ratio of phytocannabinoids. The plasma levels of CCL2 and IL17 were reduced in non-naïve cannabis users irrespective of the cohorts. We detected a significant increase in the endocannabinoid arachidonoylethanolamine (AEA) in serum from individuals with MS compared to control subjects, and no significant difference in levels of other endocannabinoids and signaling lipids irrespective of Cannabis use. Chronic Cannabis use may affect the immune response to similar extent in individuals with MS and control subjects through the ability of phytocannabinoids to reduce both monocyte migration and cytokine levels in serum. From a panel of signaling lipids, only the levels of AEA are increased in individuals with MS, irrespective of Cannabis use or not. Our results suggest that both MS cases and controls respond similarly to chronic Cannabis use with respect to the immune parameters measured in this study.
Introduction
The plant Cannabis (CB), known since antiquity for its medicinal qualities, synthesizes over 400 metabolites that collectively participate in producing its biological and Electronic supplementary material The online version of this article (doi:10.1007/s10787-014-0214-z) contains supplementary material, which is available to authorized users. therapeutic effects (ElSohly 2007; Russo 2007) . The most abundant phytocannabinoid (pCB) is D 9 -tetrahydrocannabinol (THC), known for the psychoactive, analgesic and anti-inflammatory effects that it produces. The studies of the molecular mechanisms underlying effects produced by THC led to the discovery of the cannabinoid CB 1 and CB 2 G protein-coupled receptors, endocannabinoid (eCBs) ligands and their modulatory function in many cell types (Pertwee 1997; Felder and Glass 1998; Stella 2010; Tanasescu and Constantinescu 2010; Downer 2011; Pini et al. 2012) . CB 1 receptors are expressed at a high level by neural cells while CB 2 receptors are predominately expressed by hematopoietic cells. Many other protein targets and receptors are modulated by pCBs and eCBs. The extent and action by which these non-CB 1 /CB 2 targets mediate some of the biological and therapeutic properties carried by Cannabis have been described in detail elsewhere (Howlett et al. 2002; Mackie and Stella 2006; Pertwee et al. 2010; Zhao and Abood 2012; Abood et al. 2013) .
It is well known that regimented use of pCB may induce prolonged immunosuppressive and anti-inflammatory effects (Klein 2003 (Klein , 2005 . Clinical studies show that heavy use of smoked Cannabis decreased lymphocyte proliferation and suppressed cell-mediated immunity (Gaoni 1964; Nahas et al. 1974 Nahas et al. , 1977 . Peripheral blood mononuclear cells from chronic smokers have altered basal levels of the ratio of CB 1 :CB 2 cannabinoid receptors compared to controls (Nong et al. 2002) . Furthermore, THC acting on T cells induces a shift toward a T H 2 phenotype in animal models of infection (Newton et al. 1994; Massi et al. 2000; Smith et al. 2000) . Accordingly, longterm Cannabis use decreases T cell proliferation and IL-2 levels (a T H 1 cytokine), and increases IL-10 levels (a T H 2 cytokine) in human blood (Pacifici et al. 2003 (Pacifici et al. , 2007 . Thus, chronic use of Cannabis might bias immune effector mechanisms thereby affecting autoimmune reactions such as in MS.
The phenotype of circulating monocytes is relatively 'plastic', evidenced by cell-surface protein expression profiles, migratory potentials and differential cytokine secretion in response to specific environmental cues (Murray and Wynn 2011) . Accordingly, phenotypic variability in circulating monocytes will influence the phenotype of the ensuing tissue macrophages. Evidence shows that pCB are likely to modulate the phenotype of circulating monocytes. A single low dose of THC in mice induced recruitment of bone marrow monocytes (myeloidderived suppressor cells, MDSC) into blood and alter cytokine release (also using cannabidiol (CBD, the second most abundant pCB) (Hegde et al. 2011 ). This direct modulation of the phenotype of MDSCs induced a fourfold increase in CD11bGR1
? cells (Hegde et al. 2011) . MDSC are known to inhibit T cell proliferation in humans after viral illness (Simmons 2001; McCoy et al. 2006; De Santo et al. 2008; Hegde et al. 2010; Mameli et al. 2012) . Together, these studies provide a mechanistic framework indicating that regimented use of pCB might affect the phenotype of circulating monocytes. Prevalence of medicinal Cannabis use by individuals with MS is estimated at 14 % in Nova Scotia, 17 % in Spain and 22 % in the UK (Clark et al. 2004; Ware et al. 2005 , Martinez-Rodriguez et al. 2008 . Given the critical role of circulating immune cells in MS and the immunomodulatory actions of pCB on these cells, we sought to determine if Cannabis use differentially modulates three parameters: ex vivo migration of circulating monocytes (Sexton 2012) , quantity of cytokines and eCB released in serum.
Methods and materials
Subjects and study design Subjects were recruited from 2009 to 2011 from the MS Center at the University of Washington (UW), the MS Center at Swedish Hospital in Seattle, and the MS Society of Greater Seattle and from medical, nursing and research staff at UW with approval from the UW Human Subjects Committee. Subjects were screened by telephone for inclusion/exclusion criteria prior to enrollment. Written informed consent was obtained prior to fasting, ante-cubital venipuncture using an approved protocol. Individuals with stable MS either were or were not currently using diseasemodifying therapy (DMT) and we controlled for an equal number in each arm as a control for potential effects on our outcome measures. In addition, all subjects were asked not to use ibuprofen on the day prior to their blood draw, as part of the protocol. Subjects were stratified based on current Cannabis exposure.
All subjects were C21 and B50. MS Diagnostic criteria: positive diagnosis in the last 10 years of relapsing-remitting MS (made by a neurologist, according to international guidelines); an EDSS score between 3 and 5; not currently in exacerbation and no exacerbation less than 30 prior to the blood draw. Exclusion criteria: BMI B19 and C27; diagnosis of diabetes; diagnosis of other chronic inflammatory or autoimmune disease; current pregnancy; previous DSM IV diagnosis; tobacco use or currently a performance athlete. These criteria were to minimize variables influencing the eCS or immune function. Subjects were stratified and matched by Cannabis exposure: nonnaïve is current Cannabis use at least 2-3 times per week; and naïve, is 'never used' or no history of use in the last 3 years.
Monocyte isolation and migration
The buffy coat was collected from centrifuged whole blood using BD Vacutainer Ò CPT Cell Preparation Tubes with sodium citrate (VWR Scientific, San Francisco, CA, USA). The buffy coat was washed with PBS (30 ml, centrifuged at 3,000 rpm 9 15 min). The resulting pellet was re-suspended in buffer and monocytes were isolated using an ex vivo deletion using the Midi Macs TM cocktail kit (indirect cell labeling by negative selection). The cells retained on a magnetized column are positive for CD3, CD7, CD16, CD19, CD56, CD123 and CD235a; unlabeled cells passing through the magnet are CD14
? . Serum was flash frozen at -80°C for cytokine and eCB analysis.
The modified Boyden chamber cell migration assay was previously described (Miller and Stella 2009; Sexton et al. 2012) . Briefly, filters (pore diameter = 5 lm) were coated with human fibronectin (10 lg/ml in PBS for 30 min). Isolated CD14
? monocytes were fluorescently labeled with DRAQ-5 (700 nM, 10 min at 37°C in RPMI 1,640 supplemented with 0.1 % BSA). Cells were rinsed in RPMI (0.1 % BSA) and resuspended for a final density of 10 4 cells per upper well (390 ll). Lower wells were loaded with media (82 ll) containing vehicle (0.1 % DMSO for basal migration) or the chemoattractant. Detection was by Odyssey Ò Imaging system (Li-COR Biosciences, Lincoln, NE, USA). pCB 'mix' was a set ratio of 5.2 consisting of 1 lM THC/100 nM CBN/300nM CBD (Broseus et al. 2010 ).
Cytokine analysis
Levels of 10 human cytokines/chemokines (CCL2, IFN-c, IL-2, IL-4, IL-6, IL-10, IL-13, IL-17, MIP1a and TNF-a) from human plasma were determined using a custom multiplex microbead-based immunoassay kit (Millipore, Billercia, MA, USA). Undiluted human plasma samples were assayed according to the manufacturer's protocol and analyzed using Luminex (Liquichip, Qiagen, Valencia, CA, USA). T H 1 cytokines were: IFN-c, IL-2, IL-10; T H 2 cytokines were: IL-4, IL-6 and IL-13.
Endocannabinoid analysis
Serum samples were analyzed by liquid chromatography mass spectrometry (LC-MS). Two milliliters of serum was collected within 30 min after centrifugation of whole blood (at room temperature). Proteins were precipitated using 2 volumes of ice-cold methanol and centrifuged. Samples were completely dried down under a stream of nitrogen and flash frozen until the time of analysis. Plasma samples were reconstituted in 1 ml chloroform:methanol (2:1 containing 34.8 mg PMSF/ml) from which 200 ll aliquots were mixed with 50 ll of each of deuterated internal standards (Cayman Chemicals, USA) and mixed with 2.8 ml chloroform: methanol (2:1 containing 34.8 mg PMSF/ml). Samples were vortexed and 0.6 ml of 0.73 % w/v NaCl was added to each sample, vortexed again and then centrifuged for 10 min at 3,2209g 4°C. The aqueous phase plus debris was collected and extracted again twice with 1.6 ml chloroform. The organic phases from the three extractions were pooled and evaporated under nitrogen gas. The dried samples were reconstituted with 0.1 ml chloroform and mixed with 1 ml cold acetone. The mixtures were then centrifuged for 5 min at 1,8119g and 4°C to precipitate the proteins. The upper layer of each sample was collected and evaporated under nitrogen. Dried samples were reconstituted with 0.1 ml methanol and placed in auto sample vials for analysis.
The LC-MS method has been previously described (Ramesh et al. 2011) . Briefly, LC-MS/MS was used to quantify anandamide (AEA), 2-Arachidonyl Glycerol (2-AG) palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and arachidonic acid (AA). The mobile phase consisted of (10:90) water/methanol with 0.1 % ammonium acetate and 0.1 % formic acid. The column used was a Discovery HS C18, 2.1 9 150 cm, 3 micron (Supelco, PA, USA). A calibration curve was constructed based on linear regression using the peak area ratios of the calibrators. The extracted standard curves ranged from 0.039 to 40 pmol for AEA, from 0.0625 to 64 nmol for 2-AG, from 0.039 nm to 1.25 nm for PEA and OEA and from 1 nm to 32 nm for AA. (Deuterated compound concentrations: 2 pmol AEA-d8, 1 nmol 2-AG-d 8 , 3.3 nmole PEA-d4, 3 nmole OEA-d4 and 1 nmole AA-d8).
Materials

Miltenyi LD Midi Macs
Ò separation unit and monocyte isolation kit II (Miltenyi Biotech Inc., Auburn, CA, USA). Gibco Ò RPMI1640 (Invitrogen, Carlsbad, CA, USA). DRAQ-5 TM (Axxora, San Diego, CA, USA). Multiplex microbead-based immunoassay kit (Millipore, Billercia, MA, USA). Luminex instrument (Liquichip, Qiagen, Valencia, CA, USA). AEA, 2-AG, PEA, OEA and AA (Cayman Chemical, Ann Arbor, MI, USA).
Study design
This case control, cross-sectional study was designed to take a 'snapshot' of potential immunological effects of chronic Cannabis use. To control for immunomodulating effects of DMTs, consistent numbers of DMT-naïve (n = 4) and non-naïve (n = 3) MS cases were using interferon beta-1a (Avonex Ò or Rebif Ò ). Subjects were not administered any Cannabis, but were self-accessing this botanical medicine under a law passed in Washington State in 1998 allowing for its' medical use. Healthy controls were recreational Cannabis users. Here we compare outcome measures between individuals with MS and healthy subjects assessing whether Cannabis exposure is an effect modifier of quantitative measurements in defined immune parameters.
Statistical analysis
Data for monocyte migration and cytokine analysis were analyzed with Prism Ò 4.0 software (Graphpad, San Diego, CA, USA) using two-way ANOVA followed by Bonferroni's post-test. Data for eCB were analyzed with and STATA IC 11.0 (StataCorp, College Station, TX, USA) using two-tailed, paired t tests. Results are expressed as mean ± SEM. Point estimates for the odds ratio and 95 % confidence interval (CI) were calculated using STATA IC (StataCorp, College Station, TX, USA).
Results
Eleven healthy subjects and ten individuals with MS were enrolled (Table 1) . On the day of blood draw, subjects were matched by age, BMI and cannabinoid use (i.e., naïve versus non-naive). Isolated monocytes were tested to evaluate whether pCBs regulate the migration of these cells (Miller and Stella 2009; Sexton et al. 2012 ). In vitro monocyte migration was insensitive to acute treatment with a set ratio of three pCBs when cells were isolated from either healthy subjects or from individuals with MS also naïve to cannabis (Fig. 1) . By contrast, acute treatment with pCBs significantly inhibited the migration of monocytes isolated from both healthy subjects non-naïve to cannabis and individuals with MS non-naïve to cannabis.
There were no significant differences in serum levels of CCL2 across cohorts (Fig. 2a) . Serum levels of IL17 were significantly reduced in non-naïve subjects, whether cases or controls (Fig. 2b) . Cases and controls with Cannabis exposure had reduced levels of both T H 1 and T H 2 cytokines compared to naïve subjects (Fig. 2c, d : T H 1 cytokines were below the limit of detection of the assay for the nonnaïve subjects).
There was a statistically significant increase in levels of AEA (p = 0.04) in cases compared to controls (Fig. 3a) .
Serum levels of 2AG (p = 0.14), PEA (p = 0.99) OEA (p = 0.08) and AA (p = 0.09), were not significantly different between healthy controls and MS cases (Fig. 3b-e) .
Discussion
Current strategies for MS attempt to reduce or stop the migration of T cells toward the brain. Despite a wealth of evidence pointing to the role of the eCB system in the pathogenesis of MS, there is little data on the migratory potential of monocytes isolated from human subjects and individuals with MS. Pertwee (2002) Since brain macrophages and microglia accumulate in MS lesions, changes in circulating monocytes are likely to influence overall disease progression (Kouwenhoven et al. 2001; Shechter and In patients with MS, two non-naïve subjects were on no diseasemodifying therapy (DMT) Of the naïve subjects, three were on DMTs (Rebif, Avonex.) Fig. 1 Freshly isolated monocytes respond differentially to pCB stimulation. Cell migration of freshly isolated human monocytes was significantly reduced by addition of phytocannabinoids (pCB Mix) to the lower wells of the migration chamber. There was a 50 % reduction in monocyte migration in Cannabis users, both in healthy controls and MS cases. (2-way ANOVA followed by Bonferroni's post-test) Schwartz 2012). Thus, specifically targeting circulating monocytes might influence brain repair by modifying the phenotype of these cells as they become brain macrophages.
Since Cannabis therapy may be for symptom palliation by individuals with MS (Boven et al. 2006; Mikita et al. 2011) , we addressed the question: ''Does chronic Cannabis use induce a phenotypic change in circulating monocytes?'' Monocyte cell migration was significantly inhibited by a mixture of pCBs in non-naïve subjects irrespective of whether these individuals are cases or controls. We previously reported that subjects naïve to Cannabis have an increased migratory response to CCL2 (Sexton et al. 2012) . CCL2 (monocyte chemo-attractant protein 1, MCP1) provides a strong chemotactic cue for monocytes, guiding these cells to inflammatory lesion sites throughout the body, including the brain (Conductier et al. 2010) . Our results suggest that while cannabis use affects the cell migration properties of circulating monocytes, it does not affect the serum levels of CCL2, a major chemotaxic cue for these cells (Fig. 2a) .
Our results suggest that chronic CB use may lead to global reduction of cytokines (Fig. 2b, c Katona et al. 2005) . Differences between this study and other trials include the fact that these were prospective studies where a protocol included known and standardized doses of cannabinoids, administered regularly. Here we had an observational approach to probe patients who were self-titrating at an unknown dose and rate. Additionally, differences in administration, such as oral versus inhaled, and administration of products having various cannabinoid ratios may yield different results. A balance in T H 1 and T H 2 cytokines is important in controlling the progression of both EAE and MS pathogenesis. Specifically, EAE and MS are T H 1-driven and there is compelling data that a T H 2 shift would be beneficial for achieving a desired anti-inflammatory response by the immune system (Kennedy and Karpus 1999; Oreja-Guevara et al. 2012) . However, our results extend previous studies showing that Cannabis use may globally suppress cytokine production. IL17-producing T cells (T H 17) are important players in a number of autoimmune processes and IL17 is considered to be a key player in the cytokine milieu in patients with MS, a putative biomarker for disease activity and predictor of drug response in MS (Axtell et al. 2010; Hecker et al. 2011; Li et al. 2011; Chen et al. 2012; Frisullo et al. 2008; Kallaur et al. 2013; Kozela et al. 2013) . Notable in this study is the global suppression of IL17 in subjects who are exposed to Cannabis, as cannabinoids were shown elsewhere to decrease the Th17-associated autoimmune phenotype (Kozela et al. 2013) . Our cytokine results suggest general immunosuppression instead of immune biasing, an environment likely to regulate the phenotype of circulating monocytes. These innate effector cells might be targets for immunotherapeutic strategies that guide the innate immune reaction (Downer 2011) . Further studies are required to extend our results.
eCB levels in human serum change in disease states such as obesity, Alzheimer's disease, schizophrenia, depression and liver cirrhosis (De Marchi et al. 2003; Hill et al. 2009; Koppel et al. 2009; Caraceni et al. 2010; Matias et al. 2012) . Little is known about eCBs in MS and previously published data on serum eCBs levels in individuals with MS were inconclusive (Jean-Gilles et al. 2009 ). Our results suggest that AEA levels may be increased in individuals with MS. A change in eCB signaling is not apparently sufficient to affect disease process in MS, but may participate in MS progression (Pryce and Baker 2012) . Specifically, since AEA has been suggested to be neuroprotective and have an anti-inflammatory profile in CNS parenchyma (Correa et al. 2009; Eljaschewitsch et al. 2006) , eCB changes likely influence both immune response and resulting cell damage in brain tissue.
Drugs that boost eCB signaling system are thought to induce both palliative and neuro-protective responses by tempering the immune response, promoting oligodendrocyte survival, reducing demyelinated lesions and attenuating neuronal loss. These results were obtained by studying the EAE mouse model, a T cell-mediated autoimmune disease often used to study MS (Jackson et al. 2005; Pryce and Baker 2007; Rog et al. 2007; Kuerten 2011; Notcutt et al. 2012 ) With regard to individuals with MS, an oral-mucosal spray that delivers a standardized 1:1 ratio of THC:CBD has been shown to be effective for treating refractory spasticity in MS with few side effects and low potential for addiction (Wade et al. 2010; SastreGarriga et al. 2011) .
The odds ratio (OR) that Cannabis use is more likely in cases versus controls is 0.36 (95 % CI 0.40-2.89, Fisher's exact p = 0.39). The interpretation of the OR is that the odds for exposure to (likelihood to use) Cannabis is 64 % (non-significant) lower in MS cases than in controls in our study population. We also acknowledge that the small sample size and underpowering may not be adequate for firm conclusions as our original enrollment (powered for eCB measurement) was 18 subjects for each cohort.
In summary, our results suggest a model wherein pCB (in a whole plant context) are affecting monocyte phenotype, cytokine production and eCB signaling molecules (Palazuelos et al. 2008) . The combined effects of eCB modulation are: (a) skewing the phenotype of select immune cells toward a potentially anti-inflammatory phenotype; and (b) contributing to global immune suppression by a decrease in cytokine production. Our results provide Using a bead array assay we measured CCL2, IL17 and panels of Th 1 and Th 2 cytokines. a There was no significant difference in the level of CCL2 across cohorts. b Levels of IL17 were significantly reduced in both cohorts who were current Cannabis users (non-naïve), compared to naïve subjects. c, d Levels of both Th 1 and Th 2 cytokines were significantly suppressed (undetectable in some cases) in current Cannabis users compared to naïve subjects (2-way ANOVA followed by Bonferroni's posttest) Fig. 3 Serum levels of endocannabinoids (eCB): Using HPLC/MS/MS we measured serum levels of 5 eCBs. a Serum AEA levels were elevated in patients with MS compared to controls. b-e We found no significant differences in the levels of 2AG, AA, PEA or OEA between healthy controls and MS cases. However, there was a trend for elevated 2AG and AA in patients with MS compared to controls. These data are not presented as stratified for Cannabis exposure as there were no significant differences in that regard (two-tailed, paired t tests) the foundation for exploring potential mechanisms as well as conducting prospective human trials to investigate the effects of supplementing individuals with MS with regimented intake of pCB and measuring the long-term effects on inflammatory response and disease outcome in MS.
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